Search

Displaying results 81 - 90 of 450 in total
  1. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 ...

  2. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for addition...

  3. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. … Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric

  4. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Active and viable hematopoietic progenitor cells, or hematopoietic stem cells (HSCs) express the cell surface marker CD34 which is critical for cell identification [A32216].

  5. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    It is available OTC in Europe.

  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  7. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

  9. Drug

    Sultopride

    go.drugbank.com/drugs/DB13273
    Approved

    Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics [L5626].

  10. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.